Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon (Q33464837)

27 July 2017

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon (English)

1 reference

27 July 2017

1 reference

15

Alexander M M Eggermont

1 reference

27 July 2017

Lars Bastholt

6

0 references

Stefan Suciu

2

object named as

Stefan Suciu

1 reference

27 July 2017

Marna G Bouwhuis

1

1 reference

27 July 2017

Sandra Collette

3

1 reference

27 July 2017

Steinar Aamdal

4

1 reference

27 July 2017

Wim H Kruit

5

1 reference

27 July 2017

Ulrika Stierner

7

1 reference

27 July 2017

François Salès

8

1 reference

27 July 2017

Poulam Patel

9

1 reference

27 July 2017

Cornelis J A Punt

10

1 reference

27 July 2017

Micaela Hernberg

11

1 reference

27 July 2017

Alain Spatz

12

1 reference

27 July 2017

Timo L M ten Hagen

13

1 reference

27 July 2017

Johan Hansson

14

1 reference

27 July 2017

EORTC Melanoma Group and the Nordic Melanoma Group

16

1 reference

27 July 2017

language of work or name

English

0 references

publication date

9 June 2009

1 reference

Journal of the National Cancer Institute

27 July 2017

1 reference

27 July 2017

101

1 reference

27 July 2017

12

1 reference

27 July 2017

869-877

1 reference

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.

27 July 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP132

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP132

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP132

Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP132

Range of antinuclear antibodies in "healthy" individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP132

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP132

Psychiatric symptoms before systemic lupus erythematosus is diagnosed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP132

Analysis of survival by tumor response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP132

Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP132

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP132

Anticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJP132

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJP132

1 reference

27 July 2017

1 reference